Back to search

Article

Investigation of FANCD2 in triple negative breast cancer

2019-01-01

Abstract excerpt

Despite triple negative breast cancer (TNBC) representing between 10 % to 15 % of all breast cancers, no important therapeutic advances have been developed since the introduction of taxanes as an adjuvant therapy over 20 years ago. In order to develop novel therapies for TNBC patients, a thorough understanding of the vulnerability of components of the DNA damage response (DDR), involved in the survival and progres...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0fe4461c-27eb-56bf-bbe8-65ce78e8049d
DOI
10.17638/03046847
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Investigation of FANCD2 in triple negative breast cancerDOI 10.17638/03046847
Select a neighboring publication to make it the new centre.